Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

[Global warming : a cardiovascular risk factor in it's own right].

Revue medicale de Liege·2026
Same author

Evaluating the feasibility of a novel multidisciplinary residential rehabilitation program for managing fatigue in patients with spontaneous coronary artery dissection.

European journal of cardiovascular nursing·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Exploring Sex-Specific High-Sensitivity Cardiac Troponin Thresholds for Rule-Out of Non-ST-Elevation Myocardial Infarction.

Clinical chemistry·2026
Same author

Vessel-Specific Differences in Fractional Flow Reserve Among Intermediate Coronary Lesions.

Journal of clinical medicine·2026

相关实验视频

Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

没有心力衰竭的患者心肌梗塞后的β- 阻塞剂

John Munkhaugen1,2, Anna Meta D Kristensen3, Sigrun Halvorsen4,5

  • 1Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.

The New England journal of medicine
|September 1, 2025
PubMed
概括

心肌梗塞后的β- 阻断剂治疗显著降低了被保存的喷射分数患者的死亡或重大心血管不良事件的风险. 这一发现支持在心肌梗塞后治疗中使用β抑制剂.

更多相关视频

A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

相关实验视频

Last Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

科学领域:

  • 心脏病学
  • 临床试验
  • 药理学

背景情况:

  • 已确立的β-阻断剂证据早于现代的再注血和二次预防策略.
  • 目前的指导方针要求更新心肌梗塞后治疗的证据.

研究的目的:

  • 评估心脏病发作后的β抑制剂治疗的长期疗效.
  • 评估β抑制剂对死亡率和主要心血管不良事件 (MACE) 的影响,患者左心室排气分数 (LVEF) ≥40%.

主要方法:

  • 在丹麦和挪威进行盲目的终点评估的开放性随机试验.
  • 在14天内,有5574名心脏病发作和LVEF≥40%的患者被随机分为1:1接受β- 阻断剂或不服用β- 阻断剂.
  • 主要终点:综合所有死因或MACE (心脏病发作,再血管,中风,心力衰竭,心室节律失常).

主要成果:

  • 随访时间中位数为3. 5年.
  • 在非β抑制剂组 (n=2783) 中,主要终点事件为14. 2%,而非β抑制剂组 (n=2791) 中为16. 3% (HR为0. 85;P=0. 03).
  • 使用β- 阻断剂观察到心脏病发作风险降低 (HR 0. 73);无任何原因死亡或其他MACE成分的显著差异. 安全性结果相似.

结论:

  • 在LVEF患者中,β抑制剂治疗显著降低了死亡或MACE的风险≥40%.
  • 结果支持继续使用β- 阻断剂作为MI后二次预防的基石.